Verifying…
Home / Drug A–Z / Bupivacaine Hydrochloride with Dextrose Injection

Bupivacaine Hydrochloride with Dextrose Injection

NAFDAC Reg. No. C4-1812 · Drug

Registered with NAFDAC — registration activeAs of 6 November 2026 · synced automatically from official sources.
Product
Bupivacaine Hydrochloride with Dextrose Injection
NAFDAC number
C4-1812
Active ingredient
Bupivacaine hydrochloride; Dextrose
Strength
0.5%; 8%
Form
Solution for injection
Pack size
4 mL x 5's (in vials)
Manufacturer
Not listed
Applicant (holder)
Phillips Pharmaceuticals (Nigeria) Limited
Approved
26 Aug 2021
Status
Inactive View on NAFDAC ↗
Registration valid to
25 Aug 2026
WHO alerts
None found
Community reports
None
Times checked
0

RxVerify commentary

  • Bupivacaine Hydrochloride with Dextrose Injection is on the NAFDAC register with an active registration (C4-1812). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. Not medical advice — always follow your doctor or pharmacist.

What Bupivacaine Hydrochloride with Dextrose Injection is used for

From the official U.S. FDA label for bupivacaine hydrochloride, the active ingredient registered with NAFDAC.

What it is used for

1. INDICATIONS AND USAGE Bupivacaine liposome injectable suspension is indicated to produce postsurgical: Local analgesia via infiltration in adults Regional analgesia via an interscalene brachial plexus nerve block in adults Limitations of Use The safety and effectiveness of bupivacaine liposome injectable suspension have not been established to produce postsurgical regional analgesia via other nerve blocks besides an interscalene brachial plexus nerve block. Bupivacaine liposome injectable suspension contains bupivacaine, an amide local anesthetic, and is indicated to produce postsurgical: Local analgesia via infiltration in adults ( 1 ). …

Possible side effects

6. ADVERSE REACTIONS The following serious adverse reactions have been associated with bupivacaine hydrochloride in clinical trials and are described in greater detail in other sections of the labeling: Central Nervous System Reactions [ see Warnings and Precautions ( 5.1 ) ] Cardiovascular System Reactions [ see Warnings and Precautions ( 5.1 ) ] Allergic Reactions [ see Warnings and Precautions ( 5.1 ) ] Chondrolysis [ see Warnings and Precautions ( 5.1 ) ] Methemoglobinemia [ see Warnings and Precautions ( 5.1 ) ] Accidental intravascular injection [ see Warnings and Precautions ( 5.2 ) ] Adverse reactions reported with an incidence greater than or equal to 10% following bupivacaine lipos …

Do not use if

4. CONTRAINDICATIONS Bupivacaine liposome injectable suspension is contraindicated in obstetrical paracervical block anesthesia [ see Use in Specific Populations ( 8.1 ) ]. While bupivacaine liposome injectable suspension has not been tested with this technique, the use of bupivacaine HCl with this technique has resulted in fetal bradycardia and death. Bupivacaine liposome injectable suspension is contraindicated in obstetrical paracervical block anesthesia ( 4 ).

Warnings

5. WARNINGS AND PRECAUTIONS Monitor cardiovascular status, neurological status, and vital signs during and after injection of bupivacaine liposome injectable suspension ( 5.1 ). Because amide-type local anesthetics, such as bupivacaine, are metabolized by the liver, use bupivacaine liposome injectable suspension cautiously in patients with hepatic disease. Patients with severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of developing toxic plasma concentrations ( 5.1 ). Methemoglobinemia: Cases of methemoglobinemia have been reported in association with local anesthetic use ( 5.1 ). …

Pregnancy & breastfeeding

8.1 Pregnancy Risk Summary There are no studies conducted with bupivacaine liposome injectable suspension in pregnant women. In animal reproduction studies, embryo-fetal deaths were observed with subcutaneous administration of bupivacaine to rabbits during organogenesis at a dose equivalent to 1.6 times the maximum recommended human dose (MRHD) of 266 mg. …

Storage

Storage Store bupivacaine liposome injectable suspension vials refrigerated between 2° to 8°C (36° to 46°F). Bupivacaine liposome injectable suspension may be held at a controlled room temperature of 20° to 25°C (68° to 77°F) for up to 30 days in sea …

General information only — not dosing advice. Always follow the leaflet in your pack and your doctor or pharmacist.

Check your pack of Bupivacaine Hydrochloride with Dextrose Injection

Add the expiry date printed on your pack for a full Trust Score — or look up uses, side effects and cheaper generics.

3 free checks left today · no signup Official sources: NAFDAC Green Book & recalls · WHO · U.S. FDA · NLM RxNorm

About Bupivacaine Hydrochloride with Dextrose Injection

What is in Bupivacaine Hydrochloride with Dextrose Injection?

Bupivacaine Hydrochloride with Dextrose Injection contains Bupivacaine hydrochloride; Dextrose (0.5%; 8%), as solution for injection, according to its NAFDAC registration record.

Is Bupivacaine Hydrochloride with Dextrose Injection registered with NAFDAC?

Yes. Bupivacaine Hydrochloride with Dextrose Injection is listed on the NAFDAC register under registration number C4-1812, and its registration is active as of 6 November 2026.

Has Bupivacaine Hydrochloride with Dextrose Injection been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Bupivacaine Hydrochloride with Dextrose Injection in our automatically synced alert list.

How can I check that my pack of Bupivacaine Hydrochloride with Dextrose Injection is genuine?

Run a free authenticity scan with the NAFDAC number C4-1812, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

What is Bupivacaine Hydrochloride with Dextrose Injection used for?

1. INDICATIONS AND USAGE Bupivacaine liposome injectable suspension is indicated to produce postsurgical: Local analgesia via infiltration in adults Regional analgesia via an interscalene brachial plexus nerve block in adults Limitations of Use The safety and effectiveness of bupivacaine liposome injectable suspension have not been established to produce postsurgical regional analgesia via other n (Summarised from the official U.S. FDA label for bupivacaine hydrochloride. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Bupivacaine Hydrochloride with Dextrose Injection? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from RxVerify users, not medical advice. Report side effects to your doctor and to NAFDAC.